1. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae
    Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; N Engl J Med. 2006 Apr 6;354(14):1455-63.
  2. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study
    Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C, Thomas T, Deuffic-Burban S, Prevot MH, Domart M, Tarantola A, Abiteboul D, Deny P, Pol S, Desenclos JC, Puro V, Bouvet E. Clin Infect Dis. 2005 Nov 15;41(10):1423-30
  3. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, Wang E, Mills E. JAMA. 2005 Jun 22;293(24):3003-11.
  4. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Oxman MN, Levin MJ, Johnson GR, et al. N Engl J Med. 2005 Jun 2;352(22):2271-84.
  5. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea.
    DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Ann Intern Med. 2005 May 17;142(10):805-12.
  6. Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.
    Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM; Georgia Lancet. 2005 Mar 2;365(9462):855-63.
  7. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review
    Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Lancet. 2005 Feb 26;365(9461):773-80.
  8. Capsule Switching among C:2b:P1.2,5 Meningococcal Epidemic Strains after Mass Immunization Campaign, Spain.
    Alcal? B, Arreaza L, Salcedo C, Uria MJ, De La Fuente L, V?zquez JA. Emerg Infect Dis. 2002 Dec;8(12):1512-4.